The mRNA expression of SETD2 in human breast cancer: correlation with clinico-pathological parameters.
BACKGROUND
SET domain containing protein 2 (SETD2) is a histone methyltransferase that is involved in transcriptional elongation. There is evidence that SETD2 interacts with p53 and selectively regulates its downstream genes. Therefore, it could be implicated in the process of carcinogenesis. Furthermore, this gene is located on the short arm of chromosome 3p and we previously demonstrated that the 3p21.31 region of chromosome 3 was associated with permanent growth arrest of breast cancer cells. This region includes closely related genes namely: MYL3, CCDC12, KIF9, KLHL18 and SETD2. Based on the biological function of these genes, SETD2 is the most likely gene to play a tumour suppressor role and explain our previous findings. Our objective was to determine, using quantitative PCR, whether the mRNA expression levels of SETD2 were consistent with a tumour suppressive function in breast cancer. This is the first study in the literature to examine the direct relationship between SETD2 and breast cancer.


METHODS
A total of 153 samples were analysed. The levels of transcription of SETD2 were determined using quantitative PCR and normalized against (CK19). Transcript levels within breast cancer specimens were compared to normal background tissues and analyzed against conventional pathological parameters and clinical outcome over a 10 year follow-up period.


RESULTS
The levels of SETD2 mRNA were significantly lower in malignant samples (p = 0.0345) and decreased with increasing tumour stage. SETD2 expression levels were significantly lower in samples from patients who developed metastasis, local recurrence, or died of breast cancer when compared to those who were disease free for > 10 years (p = 0.041).


CONCLUSIONS
This study demonstrates a compelling trend for SETD2 transcription levels to be lower in cancerous tissues and in patients who developed progressive disease. These findings are consistent with a possible tumour suppressor function of this gene in breast cancer.
Al Sarakbi
W
W
St George's University of London, London, UK. walsarakbi@hotmail.com
Sasi
W
W
Jiang
W G
WG
Roberts
T
T
Newbold
R F
RF
Mokbel
K
K
D001943:Breast Neoplasms / Q000235:genetics* / Q000378:metabolism / Q000473:pathology*; D005260:Female; D005500:Follow-Up Studies; D015972:Gene Expression Regulation, Neoplastic; D011495:Histone-Lysine N-Methyltransferase / Q000235:genetics* / Q000378:metabolism; D006801:Humans; D009367:Neoplasm Staging; D012333:RNA, Messenger / Q000235:genetics / Q000378:metabolism
D012333:RNA, Messenger; D011495:Histone-Lysine N-Methyltransferase; C521636:SETD2 protein, human
Hum Mol Genet. 2000 Sep 1;9(14):2175-82
10958656
Endocr Relat Cancer. 2004 Dec;11(4):781-91
15613452
J Biol Chem. 2005 Oct 21;280(42):35261-71
16118227
EMBO J. 2008 Jan 23;27(2):406-20
18157086
Gene. 1999 Nov 15;240(1):1-12
10564807
Bioessays. 2000 Sep;22(9):836-45
10944586
Int J Cancer. 2003 Sep 20;106(5):752-7
12866036
Mol Cell Neurosci. 2001 Jul;18(1):68-79
11461154
Hum Mol Genet. 1998 Sep;7(9):1463-74
9700202
Oncologist. 1999;4(2):138-9
10337384
Proc Natl Acad Sci U S A. 2005 Dec 6;102(49):17636-41
16314571
J Natl Cancer Inst. 1999 Jan 6;91(1):37-45
9890168
Nature. 2000 Jan 6;403(6765):41-5
10638745
J Pathol. 1999 Jan;187(1):112-26
10341712
Clin Cancer Res. 2003 Dec 15;9(17):6432-40
14695145
Cell Signal. 2008 Sep;20(9):1671-8
18585004
Essays Biochem. 2001;37:45-57
11758456